NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced the appointment of Thomas J Farrell as Chief Executive Officer and Director.
Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and ongoing scientific leadership at NanoSyrinx as it enters a pivotal stage of development to deliver the future of intracellular medicine.
Tom brings over 25 years of biotherapeutics leadership, with extensive experience in building and scaling organisations from early-stage drug discovery through pivotal clinical trials.
He was the founding CEO of two NASDAQ-listed companies, successfully raised over $500 million in financing from private investors, strategic partners and public markets, and has been at the forefront of next-generation therapy development in the settings of oncology, immunology and monogenic diseases.
“Tom’s exceptional track record in progressing therapies from concept to clinic, combined with his global perspective, will be invaluable as NanoSyrinx moves from platform development to establishing a robust clinical pipeline,” said Edwin Moses, Chairman of the Board at NanoSyrinx.
NanoSyrinx is entering a pivotal stage as it transitions from platform development to building a differentiated pipeline of first-in-class nanosyringe-enabled biotherapeutics.
Its breakthrough nanosyringe technology enables the precise, direct delivery of protein therapeutics into the cytosol of target cells, overcoming a major challenge in in vivo intracellular drug delivery.
Before joining NanoSyrinx, Tom was President of Oricell Therapeutics, a Shanghai-based clinical-stage CAR-T company, where he was responsible for the launch of US clinical trials and positioning the company to access US capital markets.
He has recently served as interim CEO for several innovative cell and gene therapy ventures.
